Evaluation of a human immunodeficiency virus test algorithm utilizing a recombinant protein enzyme immunoassay.
Many truly human immunodeficiency virus (HIV) antibody-negative serum samples may be unnecessarily subjected to costly and time-consuming Western blots (immunoblots). An investigation was undertaken to evaluate the efficiency of using a recombinant protein-based enzyme immunosorbent assay (EIA; Cambridge BioScience [CBC] Recombigen HIV EIA) as an adjunct to whole viral lysate EIA. A total of 2,212 serum samples which had been screened by viral lysate EIA were tested by CBC EIA in parallel with the Western blot. The sensitivity and specificity of the CBC kit were 99.9 and 99.7%, respectively. Positive and negative predictive values were 99.7 and 99.9%, respectively. The high sensitivity of this kit and its high negative predictive value make it an attractive addition to an HIV testing algorithm by reducing the number of Western blot tests on truly antibody negative serum samples.
Bureau of Laboratories and Research, Federal Centre for AIDS, Ottawa, Ontario, Canada.
D G
DG
Lepine
P W
PW
Neumann
S L
SL
Frenette
M V
MV
O'Shaughnessy
D000163:Acquired Immunodeficiency Syndrome / Q000175:diagnosis*; D000465:Algorithms; D015153:Blotting, Western; D005069:Evaluation Studies as Topic; D015483:HIV Antibodies / Q000032:analysis*; D015488:HIV Antigens / Q000276:immunology; D006801:Humans; D007124:Immunoenzyme Techniques; D011933:Reagent Kits, Diagnostic; D011994:Recombinant Proteins / Q000276:immunology; D012680:Sensitivity and Specificity
D015483:HIV Antibodies; D015488:HIV Antigens; D011933:Reagent Kits, Diagnostic; D011994:Recombinant Proteins